Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently unserved patient needs. Several rare/orphan and chronic debilitating conditions manifest with fibrosis, a complex, pathologic process in which healthy cells are replaced by progressively worsening scar tissue (fibrosis). They are committed to developing disease modifying and lifesaving treatments.
CoSec is a great business partner to work with. They offer a one-stop service to cover everything required to manage an Australian subsidiary.
Having worked with CoSec in two R&D incentive applications, I highly recommend CoSec to other biotech companies who are considering setting up a subsidiary in Australia.
CoSec has been instrumental in guiding us successfully through the R&D Tax Incentive program to conduct clinical trials in Australia. Even though I had prior experience in applying this program, I have relied heavily reply on CoSec to keep our company compliant and up to date with local changes.
VP Finance, Blade Therapeutics
Ready to Expand Your Business?
Talk to the experts who can support and guide you in your Australian and US growth journey.